288 related articles for article (PubMed ID: 27459348)
21. Subclinical phenotypes of asthma.
Bradding P; Green RH
Curr Opin Allergy Clin Immunol; 2010 Feb; 10(1):54-9. PubMed ID: 19907311
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic potential of targeting interleukin 5 in asthma.
Walsh GM
BioDrugs; 2013 Dec; 27(6):559-63. PubMed ID: 23728885
[TBL] [Abstract][Full Text] [Related]
23. Antibody therapy for the management of severe asthma with eosinophilic inflammation.
Ohta K; Nagase H; Suzukawa M; Ohta S
Int Immunol; 2017 Jul; 29(7):337-343. PubMed ID: 28910970
[TBL] [Abstract][Full Text] [Related]
24. Biologic and New Therapies in Asthma.
Tabatabaian F; Ledford DK; Casale TB
Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480
[TBL] [Abstract][Full Text] [Related]
25. Biologics or immunotherapeutics for asthma?
Tay HL; Foster PS
Pharmacol Res; 2020 Aug; 158():104782. PubMed ID: 32275962
[TBL] [Abstract][Full Text] [Related]
26. Emerging interleukin receptor antagonists for the treatment of asthma.
Al Efraij K; FitzGerald JM
Expert Opin Emerg Drugs; 2017 Sep; 22(3):275-283. PubMed ID: 28832218
[TBL] [Abstract][Full Text] [Related]
27. Mepolizumab in the treatment of severe eosinophilic asthma.
Fainardi V; Pisi G; Chetta A
Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
[TBL] [Abstract][Full Text] [Related]
28. Anti-interleukin-5 antibody therapy in eosinophilic diseases.
Simon D; Braathen LR; Simon HU
Pathobiology; 2005; 72(6):287-92. PubMed ID: 16582580
[TBL] [Abstract][Full Text] [Related]
29. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
30. Benralizumab for the treatment of asthma.
Saco TV; Pepper AN; Lockey RF
Expert Rev Clin Immunol; 2017 May; 13(5):405-413. PubMed ID: 28379047
[TBL] [Abstract][Full Text] [Related]
31. Three-step algorithm for biological therapy targeted IgE and IL-5 in severe asthma.
Oishi K; Matsunaga K
Immun Inflamm Dis; 2018 Sep; 6(3):374-376. PubMed ID: 30088345
[TBL] [Abstract][Full Text] [Related]
32. Severe asthma in the US population and eligibility for mAb therapy.
Akenroye A; McCormack M; Keet C
J Allergy Clin Immunol; 2020 Apr; 145(4):1295-1297.e6. PubMed ID: 31866437
[No Abstract] [Full Text] [Related]
33. Treatment of severe asthma: entering the era of targeted therapy.
van Buul AR; Taube C
Expert Opin Biol Ther; 2015; 15(12):1713-25. PubMed ID: 26331583
[TBL] [Abstract][Full Text] [Related]
34. New and Anticipated Therapies for Severe Asthma.
Peters SP; Busse WW
J Allergy Clin Immunol Pract; 2017; 5(5S):S15-S24. PubMed ID: 28888244
[TBL] [Abstract][Full Text] [Related]
35. Anti-interleukin 4 and 13 for asthma treatment in the era of endotypes.
Kau AL; Korenblat PE
Curr Opin Allergy Clin Immunol; 2014 Dec; 14(6):570-5. PubMed ID: 25159182
[TBL] [Abstract][Full Text] [Related]
36. Sequential Biotherapy Targeting IL-5 and IL-4/13 in Patients with Eosinophilic Asthma with Sinusitis and Otitis Media.
Chikumoto A; Oishi K; Hamada K; Hirano T; Kakugawa T; Kanesada K; Matsunaga K
Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454111
[TBL] [Abstract][Full Text] [Related]
37. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
Garrett JK; Jameson SC; Thomson B; Collins MH; Wagoner LE; Freese DK; Beck LA; Boyce JA; Filipovich AH; Villanueva JM; Sutton SA; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2004 Jan; 113(1):115-9. PubMed ID: 14699394
[TBL] [Abstract][Full Text] [Related]
38. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
39. Anti-interleukin-5 antibody therapy in asthma and allergies.
Corren J
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):565-70. PubMed ID: 21971335
[TBL] [Abstract][Full Text] [Related]
40. Asthma Phenotypes as a Guide for Current and Future Biologic Therapies.
Hamilton D; Lehman H
Clin Rev Allergy Immunol; 2020 Oct; 59(2):160-174. PubMed ID: 31359247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
